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Abstract: Multidrug-resistant tuberculosis (MDR-TB) is a global public health threat and burden
on the health system. This is especially the case in high tuberculosis (TB) prevalence countries,
such as Sudan. Consequently, this study aimed to ascertain the predictors of MDR-TB in Sudan
to provide future guidance. An unmatched case-control study to assess the predictors of MDR-TB
infections among the Sudanese population was conducted from August 2017 to January 2018 at
Abu-Anga referral hospital. Patients’ data was gathered from patients’ cards and via interviews.
A structured pre-validated questionnaire was used to gather pertinent information, which included
sociodemographic characteristics and other relevant clinical data. Univariate and multivariate logistic
regression analysis was employed to determine the predictors of MDR-TB infection. 76 of the
183 patients interviewed (41.5%) had MDR-TB cases. The independent predictors for MDR-TB were
living in rural areas [adjusted odds ratio (aOR) = 3.1 (95% confidence interval (CI): 1.2–8.2)], treatment
failure [aOR = 56.9 (10.2–319.2)], and smoking [(aOR = 4 (1.2–13.2)], whereas other sociodemographic
factors did not predict MDR-TB. In conclusion, the study showed that a history of smoking, living in
rural areas, and a previous treatment failure were the predictors of MDR-TB in Sudan. The latter
factors are most likely due to issues that are related to access and adherence to treatment and lifestyle.
The existence of any of these factors among newly diagnosed TB patients should alert clinicians for
the screening of MDR-TB. The implementation of directly observed treatment (DOT) and health
education are crucial in stopping the spread of MDR-TB in Sudan.
Keywords: MDR-TB; Predictors; Sudan; Tuberculosis
1. Introduction
The identification and management of tuberculosis (TB) is still a priority area across countries,
as it is the second leading cause of death worldwide from infectious diseases, including patients with
concomitant HIV and TB [1–4]. TB is a concern in Sudan, as it is a high TB burden country in the
Eastern Mediterranean Region/World Health Organization (EMR/WHO) [5,6]. In 2017, 21054 cases of
TB were notified in Sudan [4]. Internal displacement enhances this high incidence of TB in Sudan [7].
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Cases of multidrug-resistant tuberculosis (MDR-TB) are rising, which is a growing concern across
countries [4,8–11]. Although access to drug sensitivity tests (DST) for TB has increased, significant
gaps remain in the area of diagnosis and management of MDR-TB across countries [12]. In addition,
studies in Zimbabwe, South Africa, and Ethiopia associate high treatment default rates with leading
to the development of MDR-TB due to the extended treatment period and unwanted side-effects of
second-line anti-TB medicines [13–15]. Failure to implement Directly Observed Treatment (DOT)
also plays a major role in the existence of disease resistance, according to the WHO [16]. Moreover,
resistance to anti-TB medicines is a reflection of the poor quality of TB programs in countries and
directly impacted by sub-optimal therapeutic practices [17].
The WHO has reported that, between 2000 and 2004, 20% and 2% of TB cases were identified
as being resistant to first and second-line medications, respectively [18]. The prevalence of MDR-TB
in Sudan is higher among retreated TB cases when compared to the new cases. An epidemiologic
study that was conducted in three primary TB management units in Khartoum reported 5% and 24%
resistance among new and previously treated cases, respectively [19]. In addition, the prevalence of
MDR-TB was noted to be 19% among previously treated TB patients and 1.8% among new cases,
according to the 2012 Sudan National TB program (NTP) report [20]. However, higher rates were seen
in a study that was carried out in north-eastern Sudan at 6% among new cases [21]. This is a concern to
both the authorities and patients as the control and treatment of MDR-TB is difficult and costly [22–24].
Despite these concerns, to date, the prevalence of MDR-TB in Sudan has not been systematically
determined, which is partly due to the limited laboratory capacity [25], although the NTP published its
report in 2012. This is a key issue to address as the detection of MDR-TB and its potential predisposing
factors helps in informing the instigation of pertinent strategies to control the development of resistance,
optimize treatment costs, and lessen the burden of adverse drug reactions that are associated with the
management of MDR-TB [22–24,26]. Currently, there is only one reference laboratory in Khartoum state
that performs cultures and DST for MDR-TB patients. At a minimum, three to six weeks are needed
for the notification of drug resistant TB phenotypes by direct and indirect methods, respectively [7].
This calls for systems, such as early notification and prompt management of MDR-TB patients, to
counter the spread of the MDR-TB [12,22]. Consequently, the aim of this study was to identify the risk
factors that are associated with MDR-TB infections in Sudan, in order to help with future management
strategies and to provide guidance on the potential ways to control the spread of MDR-TB in Sudan.
2. Methods
2.1. Study Setting
This study was conducted at Abu-Anga regional referral hospital, which is located in Omdurman
city, Khartoum state, and is the main TB specialized hospital in Sudan. All of the suspected resistant
TB cases are referred to this hospital for confirmation, and it is currently the only source for MDR-TB
statistics in Sudan. The National TB Reference lab (NTBRL) only processes DST requests from this
hospital and the country office of MDR-TB focal person in Sudan is located in this hospital. NTBRL is
under the administrative umbrella of the Federal Ministry of Health (FMOH) of Sudan. Sixty-one and
thirty-one MDR-TB cases were notified and commenced treatment in the hospital in 2016 and 2017,
respectively. Of these 92 cases, 76 agreed to participate in the study, giving a participation rate of 82.6%.
2.2. Study Design and Data Collection
An unmatched prospective case-control study was conducted over a six-month period, from
August 2017 to January 2018. We adopted this design as it was seen as the most feasible and applicable
method for our study. In fact, matching was not possible, as this method assumes a large patient
population to select suitable cases for matching or a long period of time for small populations.
However, in our study, we have taken measures to reduce the possibility of confounding by recruiting
TB retreatment patients as the control. Moreover, multivariate logistic regression diminishes the
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effect of confounding. A standardized data collection form with the main determinants of MDR-TB
being taken from the literature was used to collect data from patients and TB cards. The main
outcome variable was a diagnosis of MDR-TB versus non-MDR-TB, i.e., smear-positive retreatment
cases. The cases were bacteriologically confirmed to be resistant to at least rifampicin and isoniazid,
whereas the controls were category II cases. According to the WHO definition, category II includes
previously treated patients (treatment failure, relapse, and defaulters) [27]. The covariates were
sociodemographic (e.g., age, sex, family size, occupation, and residence), clinical, and behavioral
factors, such as history of imprisonment, drug addiction, smoking, chronic use of antacids, previous TB
treatment outcome, history of contact, human immunodeficiency virus/ acquired immunodeficiency
syndrome (HIV/AIDS) co-infection, and alcohol. The inclusion of these covariates of MDR-TB in our
study is based on numerous globally published studies. The findings from a recent study that was
undertaken in East Shoa, Ethiopia, indicated that previous treatment, contact with a known TB patient,
rural residency, occupation, and alcohol consumption were all reported as the MDR-TB predisposing
factors [28]. Moreover, several studies referred at various levels to the correlation of MDR-TB with
certain sociodemographic and clinical factors. These factors included smoking, alcohol, HIV/AIDS,
level of education, occupation, previous exposure to TB, and history of TB contact [29–34]. In addition,
other factors that are related to cultural behaviors in Sudan, and some neighboring countries, such as
Ethiopia, including snuff chewing, were included.
The patients were interviewed during their regular visits to the hospital after obtaining both verbal
and written consent. A trained medical assistant working at the TB hospital conducted the interviews
and kept records. In this study, all of the MDR-TB patients who were prescribed second line anti-TB
medicines (i.e., the cases) and all of the patients on category II first-line medicines (i.e., the controls)
were targeted. New TB patients were excluded to ensure similarities between the two groups, cases and
controls, except for the determinants under investigation. We are also aware that the rate of MDR-TB
is much higher among those patients who have been previously exposed to anti-TB medicines and
whose treatment outcomes were recoded as poor treatment, in particular, treatment failures [30,34].
The aim was to keep confounding bias to a minimum.
Patients who agreed to participate were recruited. Seventy-six MDR-TB—the cases—and one
hundred and seven smear-positive—the controls—were included in the study. Ultimately, a total of
183 participants were recruited in the study.
2.3. Statistical Analysis
The data were entered onto IBM-SPSS version 24. Univariate statistical analysis of the association
between independent variables, factors under investigation and the dependent variable, and the outcome,
were undertaken and the values were considered to be significant at a p-value of less than 5%. Statistical
tests, including Chi-square or Fisher’s exact test, were used in the study. Binary logistic regression was
also used. Multiple logistic regression analysis was also employed, and the predictors of MDR-TB were
identified. The control category (i.e., the retreatment cases) was treated as the reference variable in the
outcome section. The MDR-TB status in the outcome variable was coded as one, whereas the retreatment
cases were entered as zero. Only the independent variables concluded as being significantly associated
in the binary regression analysis were employed in the multiple logistic regression to eliminate the effect
of confounding bias. Ultimately, the determinants of MDR-TB development were identified.
2.4. Ethical Approval
Ethical approval was granted by the research directorate, Federal Ministry of Health, Sudan,
with the approval number: fmoh/nhrc/rd/ec dated 29/07/2017. The purpose and expected outcomes
of the study were clearly explained to the participants. Furthermore, the interviewer informed the
participants that his/her information would be kept confidential and would not be used for any other
purpose. The form includes a briefing about the study, name, and address of the participant, as well as
Antibiotics 2019, 8, 90 4 of 11
the signatures of participants and the data collector. Only those who agreed to participate and signed
the consent form were included in the study.
3. Results
3.1. Characteristics of the Study Participants
76 (41.5%) of the 183 TB patients who participated were MDR-TB cases when compared to
107 (58.5%) controls, i.e., smear positive retreatment TB patients. 63.9% were aged 18–39 years,
and 76.5% were male (Table 1). There were no significant (p > 0.05) differences in the baseline
socio-demographic and clinical characteristics between the cases and controls, except for residency,
history of imprisonment, TB contact, previous treatment outcome, HIV coinfection, alcohol intake,
smoking, and asthma (Table 1).
Table 1. Socio-demographic and clinical characteristics of the study participants.
Variable Case (%) Control (%) Total (%) a P-value
Age group
18–39 52 (68.4) 65 (60.7) 117 (63.9)
40–54 16 (21.1) 24 (22.4) 40 (21.9) 0.40
≥55 8 (10.5) 18 (16.8) 26 (14.2)
Sex
Male 59 (77.6) 81 (75.7) 140 (76.5) 0.76
Female 17 (22.4) 26 (24.3) 43 (23.5)
Occupation
Daily laborer 64 (84.2) 85 (81) 149 (82.3)
House-wife 9 (11.8) 15 (14.3) 24 (13.3) 0.86
Employee 3 (3.9) 5 (4.8) 8 (4.4)
Educational status
No formal education 14 (18.4) 28 (26.9) 42 (23.3)
Primary school 32 (42.1) 48(46.2) 80 (44.4) 0.16
Higher secondary school 30 (39.5) 28 (26.9) 58 (32.2)
and above
Residency
Rural 55 (72.4) 42 (39.6) 97 (53.3) <0.05 *
Urban 21 (27.6) 64 (60.4) 85 (46.7)
Number of Family members
2 or less 3 (3.9) 2 (2) 5 (2.8)
3–6 28 (36.8) 33 (32.4) 61 (34.3) 0.51
More than 6 45 (59.2) 67 (65.7) 112 (62.9)
Annual income (SDG)
Less than 60000 44 (75.9) 68 (84) 112 (80.6)
60000–100000 13 (22.4) 12 (14.8) 25 (18) 0.43
More than 100000 1 (1.7) 1 (1.2) 2 (1.4)
HIV infection
Positive 2 (2.7) 30 (28.3) 32 (17.9) <0.05 *
Negative 71 (97.3) 76 (71.7) 147 (82.1)
Smoking
Yes 45 (59.2) 46 (43) 91 (49.7) 0.03 *
No 31 (40.8) 61 (57) 92 (50.3)
Chronic antacid use
Yes 16 (21.6) 36 (35) 52 (29.4) 0.06
No 58 (78.4) 67 (65) 125 (70.6)
Drug addiction
Yes 18 (23.7) 13 (13.1) 31 (17.7) 0.07
No 58 (76.3) 86(86. 9) 144 (82.3)
History of TB contact
Yes 34 (45.3) 27 (26.7) 61 (34.7) 0.01 *
No 41 (54.7) 74 (73.3) 115 (65.3)
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Table 1. Cont.
Variable Case (%) Control (%) Total (%) a P-value
Previous TB treatment outcome
Defaulter 17 (23.9) 43 (40.2) 60 (33.7)
Failure 45 (63.4) 10 (9.3) 55 (30.9) <0.05 *
Completed 7 (9.9) 16 (15) 23 (12.9)
Cured 2 (2.8) 38 (35.5) 40 (22.5)
Diabetes mellitus (DM)
Yes 12(15.8) 18(17) 30 (16.5) 0.83
No 64(84.2) 88(83) 152 (83.5)
Asthma
Yes 3 (3.9) 25 (24) 28 (15.6) <0.05 *
No 73 (96.1) 79 (76) 152 (84.4)
History of imprisonment
Yes 22 (28.9) 16 (15.1) 38 (20.9) 0.02 *
No 54 (71.1) 90 (84.9) 144 (79.1)
Chronic alcohol drinker
Yes 36 (47.4) 31 (29) 67 (36.6) 0.01 *
No 40 (52.6) 76 (71) 116 (63.4)
Snuff Chewing
Yes 38 (50) 42 (39.3) 80 (43.7) 0.15
No 38 (50) 65 (60.7) 103 (56.3)
NB: p-values were calculated from Chi-square (χ2) or Fisher’s exact test; TB = Tuberculosis; a Not all variables sum
up to 183 due to missing data; * statistically significant at p < 0.05.
3.2. Association of Socioeconomic Factors, Clinical and Behavioral Factors with MDR-TB
On binary logistic regression analysis, the crude odds ratio (OR) showed that smoking (OR 1.93,
95% confidence interval (CI) 1.1–3.5), living in rural areas (OR 4.0, 95% CI 2.1–7.5), and imprisonment
(OR 2.3 95% CI 1.1–4.7) were significantly associated with MDR-TB. Similarly, poor treatment outcomes,
including defaulters (OR 7.5, 95% CI 1.6–34.7) and treatment failure (OR 85.5, 95% CI 17.6–414.4),
as well as chronic alcohol drinking (OR 2.2, 95% CI 1.2–4.1) and the type of TB contact (OR 2.3, 95 CI
1.2–4.3), were significantly associated with MDR-TB (Table 2).
Table 2. Association of clinical and behavioral factors with multidrug-resistant tuberculosis (MDR-TB)
among MDR-TB cases.
Variables Cases Number(%) (n = 76)
Control Number
(%) (n = 107) p-Value
Crude OR
(95% CI)
HIV infection Positive 2 (2.7) 30 (28.3) <0.001 0.1 (0.02–0.3) *
Negative 71 (97.3) 76 (71.7) 1
Smoking Yes 45 (59.2) 46 (43) 0.03 1.93 (1.1–3.5) *
No 31 (40.8) 61 (57) 1
Chronic antacid use Yes 16 (21.6) 36 (35) 0.06 0.5 (0.3–1.0)
No 58 (78.4) 67 (65) 1
Drug addiction Yes 18 (23.7) 13 (13.1) 0.07 2.1 (0.9–4.5)
No 58 (76.3) 86(86. 9) 1
History of TB contact Yes 34 (45.3) 27 (26.7) 0.01 2.3 (1.2–4.3) *
No 41 (54.7) 74 (73.3) 1
Defaulter 17 (23.9) 43 (40.2) 0.01 7.5 (1.6–34.7) *
Previous TB treatment outcome Failure 45 (63.4) 10 (9.3) <0.001 85.5 (17.6–414.4) *
Completed 7 (9.9) 16 (15) 0.01 8.31 (1.56–44.45) *
Cured 2 (2.8) 38 (35.5) 1
Diabetes mellitus (DM) Yes 12 (15.8) 18(17) 0.83 0.92 (0.41–2.04)
No 64 (84.2) 88 (83) 1
Asthma Yes 3 (3.9) 25 (24) 0.001 0.13 (0.04–0.45) *
No 73 (96.1) 79 (76) 1
History of imprisonment Yes 22 (28.9) 16 (15.1) 0.03 2.29 (1.11–4.74) *
No 54 (71.1) 90 (84.9) 1
Chronic alcohol drinker Yes 36 (47.4) 31 (29) 0.01 2.21 (1.19–4.08) *
No 40 (52.6) 76 (71) 1
Snuff Chewing Yes 38 (50) 42 (39.3) 0.15 1.55 (0.86–2.80)
No 38 (50) 65 (60.7) 1
NB: OR = odds ratio; CI = confidence interval; HIV = human immunodeficiency virus; TB = Tuberculosis;
MDR-TB = multidrug-resistant tuberculosis; * statistically significant at p < 0.05.
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In contrast, HIV/AIDS comorbidity (OR 0.1, 95% CI 0.02–0.3), asthma comorbidity (OR 0.1, 95% CI
0.04 – 0.5), as well as a lack of a formal education (OR 0.5, 95% CI 0.2–1.1) and primary education
(OR 0.6, 95% CI 0.3–1.2) were not significant risk factors for MDR-TB (Table 3).
Table 3. Association of socio-demographic factors with MDR-TB among the presumptive MDR-TB cases.
Variables
MDR-TB
Number (%)
(n = 76)
Non-MDR-TB
Number (%)
(n = 107)
p-Value Crude OR(95% CI)
Age (in years)
18–39 52 (68.4) 65 (60.7) 0.21 1.8 (0.7–6.2)
40–54 16 (21.1) 24 (22.4) 0.45 1.5 (0.5–4.4)
≥55 8 (10.5) 18 (16.8) 1
Sex
Male 59 (77.6) 81 (75.7) 0.76 0.9 (0.5–1.8)
Female 17 (22.4) 26 (24.3) 1
Occupation
Daily laborer 64 (84.2) 85 (81) 0.76 1.3(0.3–5.5)
House-wife 9 (11.8) 15 (14.3) >0.05 1.0 (0.2–5.2)
Employee 3 (3.9) 5 (4.8) 1
Educational
status
No formal education 14 (18.4) 28 (26.9) 0.07 0.5 (0.2–1.1)
Primary school 32 (42.1) 48(46.2) 0.17 0.6 (0.3–1.2)
Higher secondary school 30 (39.5) 28 (26.9) 0.08 1
and above
Residency Rural 55 (72.4) 42 (39.6) <0.01 4.0 (2.1–7.5) *
Urban 21 (27.6) 64 (60.4) 1
Family
members (n)
2 or less 3 (3.9) 2 (2) 1
3–6 28 (36.8) 33 (32.4) 0.55 0.6 (0.1–3.6)
More than 6 45 (59.2) 67 (65.7) 0.39 0.5 (0.07–2.8)
Less than 60000 SDG 44 (75.9) 68 (84) 0.76 0.7 (0.04–10.6)
Annual income
60000–100000 SDG 13 (22.4) 12 (14.8) 0.96 1.1 (0.1–19.3)
More than 100000 SDG 1 (1.7) 1 (1.2) 1
NB: MDR-TB = multidrug-resistant tuberculosis; OR = odds ratio; CI = confidence interval * statistically significant
at p < 0.05.
3.3. Predictors of MDR-TB
On multivariate analysis, the regression model showed that rural residency (OR (95% CI) = 3.11 (1.2–8.2),
a history of smoking (OR (95% CI) = 4 (1.2–13.2), and poor previous TB treatment outcomes, namely, treatment
failure (OR (95% CI) = 56.9 (10.2–319.2), were predictors of MDR-TB (Table 4).
Table 4. Predictors of MDR-TB among resistant cases.
Variables Cases Number(%) (n = 76)
Control
Number (%) (n
= 107)
Crude OR
(95%CI)
Adjusted OR
(95% CI)
Residency Rural 55 (72.4) 42 (39.6) 4 (2.10–7.5) * 3.11 (1.2–8.2) *
Urban 21 (27.6) 64 (60.4) 1 1
Smoking Yes 45 (59.2) 46 (43) 1.9 (1.1–3.5) * 4 (1.2–13.2) *
No 31 (40.8) 61 (57) 1 1
HIV infection Positive 2 (2.7) 30 (28.3) 0.1 (0.02–0.3) * 0.1 (0.02–1.1)
Negative 71 (97.3) 76 (71.7) 1 1
History of TB contact Yes 41 (54.7) 74 (73.3) 2.3 (1.2–4.3) * 2.3 (0.8–6.5)
No 41 (54.7) 54 (72) 1 1
Defaulter 17 (23.9) 43 (40.2) 7.5 (1.6–34.7) * 3 (0.6–15.8)
Previous TB treatment outcome Failure 45 (63.4) 10 (9.3) 85.5(17.6–414.4) *
56.9
(10.2–319.2) *
Completed 7 (9.9) 16 (15) 8.3 (1.6–44.5) * 4.1 (0.7–24.5)
Cured 2 (2.8) 38 (35.5) 1 1
Asthma Yes 3 (3.9) 25 (24) 0.1 (0.04–0.5) * 0.3 (0.04–1.8)
No 73 (96.1) 79 (76) 1 1
History of imprisonment Yes 22 (28.9) 16 (15.1) 2.3 (1.1–4.7) * 1 (0.3–3)
No 54 (71.1) 90 (84.9) 1 1
Chronic alcohol drinker Yes 36 (47.4) 31 (29) 2.2 (1.2–4.1) * 1.1 (0.3–3.4)
No 40 (52.6) 76 (71) 1 1
NB: OR = odds ratio; CI = confidence interval; HIV = human immunodeficiency viruses; TB = Tuberculosis;
* statistically significant at p < 0.05.
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4. Discussion
We believe that this is the first comprehensive study conducted in Sudan to provide information
regarding the predictors of MDR-TB to help establish potential policies to control MDR-TB in the
country. History of treatment failure, being a rural resident, and a history of smoking were found to be
significantly associated with the occurrence of MDR-TB on multivariate analysis (Table 4).
The findings regarding the higher rates of MDR-TB among rural residents is similar to the findings
of a study that was undertaken in East Shoe, Ethiopia [28], and a previous study that was conducted in
Sudan where defaulting on TB treatment was associated with rural residency [35]. Furthermore, being
a farmer in Ethiopia was also reported to be significantly associated with MDR-TB [30]. Another study
that was conducted in Amhara National Regional State, Ethiopia, revealed that a low monthly income
was also one of the MDR-TB predictors [31], which may be seen in more rural settings. A history of
smoking was also found to be associated with the occurrence of MDR-TB (Table 2), similar to studies
that were conducted in Henan province in China, North India, and central Nepal [34,36,37].
Educational status was not significantly associated with MDR-TB in our study. This is similar to
two studies that were undertaken in Ethiopia [28,38]. However, this is different from the findings of
Rifat et al. [32] and Zhang et al. [34]. We are not sure of the reasons for these differences, and we will
be looking at this further. Even though the spread of TB is through direct contact, the current model
did not show a significant association between TB contact history and MDR-TB. This finding is in line
with a previous study in Iran, where there appeared to be no association between previous TB contact
and MDR-TB [39]. However, other studies have found an association between TB contact history and
MDR-TB [28,29,31,38,40]. Again, we will be looking at this further.
MDR-TB is most prevalent among patients who have been previously prescribed anti-TB medicines
as compared to the incidence of resistant TB among new cases [41]. Our study also revealed a significant
association between MDR-TB and failure cases. Mulisa et al. also reported that treatment failure was
statistically associated with the development of MDR-TB [30].
Our findings did not show any association with some socio-demographic factors, such as sex,
annual income, number of family members, age, and occupation (Table 3); whereas, one study that was
undertaken in India reported that females are more prone to MDR-TB than males [42]. In Bangladesh,
families of more than four members were significantly associated with MDR-TB [40], differing though
from our findings. Jitmuang et al. reported that those under 65 years are more susceptible to
MDR-TB [43], which is again in contrast to our findings. Similarly, in Shanghai, patients 46 years old
and above was seen three times more likely to get MDR-TB when compared to those less than 46 years
old [8]. We are again not sure of the reasons behind these differences and will be exploring this in
future studies.
TB is prevalent among HIV/AIDS patients, with the rate of acquisition of TB estimated to be
between 16–27 times more prevalent among HIV/AIDS as compared to those without this disease [44,45].
However, our model did not show any significant association with HIV/AIDS on multivariate analysis
(Table 4). This is similar to the finding that was reported by Mulu et al., where no significant association
was found [31]; however, our finding is different to other studies that have reported an association
between HIV/AIDS and the existence of MDR-TB [30,33]. We will also be exploring this further in
future studies given the comments from the WHO in their publications [44,45].
A history of drinking alcohol was not an MDR-TB predictor on the multivariate analysis in our
study. This is similar to the findings in the Oromia region in Ethiopia, Lithuania, and Botswana [30,46,47].
Similarly, Marahatta et al. reported no evidence of a significant association between alcohol and
MDR-TB in Nepal [36]. There was also no association between a history of imprisonment and MDR-TB
in our study, which is similar to studies in Ethiopia [28,30]. However, in other studies, prisoners,
in general, have been a particular concern, as they tend to have an appreciably higher prevalence of
TB than the general population, with prisoners typically being at high risk for developing TB due to
issues, such as substance abuse, homelessness, and mental illness [48]. These factors, combined with
poor ventilation, overcrowding, and poor diet in prisons, can enhance TB rates [48].
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Overall, the differences and similarities of factors that are associated with the development
of MDR-TB among regions and countries highlights the importance of conducting local studies to
determine local factors that are robustly associated with MDR-TB. However, any appreciable differences
in the findings between countries are a cause of concern, and they point to the need for additional
research to clarify the situation. Consequently, patients with locally identified risk factors need to be
a high priority in any local TB program until the results of any further research are known. In turn,
this would help the health authorities to curb the MDR-TB in their country [30].
In summary, on multivariate analysis, living in rural areas, history of smoking, and poor
treatment outcomes, including treatment failure, were found to be the predictors of MDR-TB in Sudan.
Consequently, the national TB program, which is the responsible body for the control of the disease in
Sudan, should maximize efforts to combat TB and anti-TB drug resistance. The National TB program
should complete the ongoing national survey to more accurately ascertain the incidence of MDR-TB in
Sudan. Besides increasing the number of treatment centers and the free provision of TB medicines,
there is also a need for programs to address and overcome the problems that are associated with rural
residency. This could include the improvement of transportation to the centers if their costs are a
concern. There is also a need to progress policies to reduce smoking, building on the momentum that
has been created in Sudan by recent initiatives (https://tobaccoatlas.org/country/sudan/). The successful
detection of new cases and their proper management will lead to appreciable improvements in
treatment outcomes of patients with TB in Sudan in the future.
5. Study Limitations
Case-control was the study design employed. This type of study is prone to recall bias, which is
the main drawback. However, this is the most applicable study design in this case. We believe our
findings are robust in providing future directions, despite these limitations.
6. Conclusions and Recommendations
The present study showed that living in rural areas, smoking, and previous poor treatment
outcomes, were significantly associated with the occurrence of MDR-TB. The reinforcement of health
education, total DOT programs coverage for all TB patients, and working on identified determinants
are highly recommended to reduce the spread of MDR-TB in Sudan. NTP-Sudan should also coordinate
with the private sector to refer TB patients to appropriate TB management units (TBMUs) to ensure
that the management of TB cases is under program supervision.
In addition, addressing concerns with rural residency and smoking where these occur, together
with an implementation of DOT programs and health education, will be crucial in stopping the spread
of MDR-TB in Sudan. We will be monitoring such developments in the future.
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